Status:
COMPLETED
Giant Cell Arteritis - Optimization of Diagnostics
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Giant Cell Arteritis
Eligibility:
All Genders
Brief Summary
Giant cell arteritis - Optimization of diagnostics
Detailed Description
A prospective study. Investigating the use of ultrasound, temporal artery biopsy, biomarkers and 18F-fluorodeoxyglucose positron emission tomography-computed tomography for establishing a diagnosis of...
Eligibility Criteria
Inclusion
- Clinical suspicion of giant cell arteritis
- Meets the American College of Rheumatology Criteria:
- Age at disease onset =\> 50 years New headache Temporal artery abnormality Elevated erythrocyte sedimentation rate \>=50 mm/hour Abnomal artery biopsy
Exclusion
- Active cancer Use of steroid for more than a week (the prior 6 months)
Key Trial Info
Start Date :
March 19 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2024
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT05248906
Start Date
March 19 2021
End Date
January 1 2024
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Denmark